TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05549531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-1004-1239 (10 mg)
Description: ACT-1004-1239 will be administered as 1 capsule of 10 mg strength to be taken under fed conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg, o.d.)
Description: Itraconazole 200 mg will be administered as capsules (2 x 100 mg capsule) to be taken under fed conditions.
Study: NCT04743687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Oral Zanuburutinib, 160mg twice a day
Study: NCT05537350

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lumenato
Description: Supplementation of 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lumenato
Description: Supplementation of 12 weeks
Study: NCT05082740

Intervention type: OTHER
Intervention: Notification of a revised breast cancer risk estimate
Description: These women will be given the opportunity to learn of their revised breast cancer risk estimate which has been re-calculated with the inclusion of new strong independent risk factors. These women will be offered a clinical consultation to discuss their risk and will a subset will be asked to take part in a qualitative interview about their experiences.
Study: NCT06067269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PSMA-PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Undergo PSMA-PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Guided Stereotactic Body Radiation Therapy
Description: Undergo guided SBRT
Study: NCT04220008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT05325528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab in Combination with Oxaliplatin and Tegafur
Description: 6 cycles of Tislelizumab plus SOX regimen every 21 days
Study: NCT06181097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: negative pressure wound therapy
Description: The intervention group will have layered closure with a 2-O Vicryl (polyglactin 910) braided suture for the subcutaneous layers and a 3-O Stratafix knotless barbed suture for the subcuticular layer. Fixation strips (STERI-Strip, 3M) would then be applied to the entire length of the wound. The Smith \& Nephew PICO dressing will be chosen as it is versatile with various size options, and the small suction pump is would not causing much problems to patient mobility.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard dressing
Description: The standard dressing group will have layered closure with a 2-O Vicryl (polyglactin 910) braided suture for the subcutaneous layers and a 3-O Stratafix knotless barbed suture for the subcuticular layer. Fixation strips (STERI-Strip, 3M) would then be applied to the entire length of the wound. The same PICO dressing will be applied, but without the suction.
Study: NCT05040854

Intervention type: GENETIC
Intervention: HLA-DQA1*05 and DRB1
Description: All patients will be asked to give blood samples to search for HLA-DQA1\*05 and DRB1

Intervention type: GENETIC
Intervention: HLA-DQA1*05 and DRB1
Description: All patients will be asked to give blood samples to search for HLA-DQA1\*05 and DRB1

Intervention type: GENETIC
Intervention: HLA-DQA1*05 and DRB1
Description: All patients will be asked to give blood samples to search for HLA-DQA1\*05 and DRB1
Study: NCT05839522

Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-care hepatitis C antibody test
Description: Qualitative point-of-care test for hepatitis C antibodies (saliva sample)

Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-care hepatitis C RNA test
Description: Hepatitis C Viral Load point-of-care test (fingerstick wholeblood sample)

Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-care hepatitis B surface antibody test
Description: Qualitative hepatitis B surface antibody point-of-care test (fingerstick wholeblood sample)

Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-care hepatitis B surface antigen test
Description: Qualitative hepatitis B surface antigen point-of-care test (fingerstick wholeblood sample)

Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-care HIV antibody test
Description: Qualitative HIV antibody point-of-care test (saliva sample)

Intervention type: BEHAVIORAL
Intervention: Interview-style survey
Description: Interview-style survey regarding demographics, risk behaviours, BBV testing and treatment history, and point-of-care testing acceptability
Study: NCT06219447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRRS Home Tablet or Medico Amico Kids APP
Description: Tele-rehabilitation (TR) permits intensive and personalized intervention monitored by clinicians in an ecological friendly, home setting. The VRRS Home Kit, comprising a tablet and peripheral devices, permits TR of cognitive, speech and motor functions. These peripherals such as sensors and balances allow motor rehabilitation across different body districts involved (upper and lower limbs, trunk). Touch screen activities, enables neuropsychological and speech therapy sessions. Medico Amico APP, offers a wide library of cognitive, language and motor exercises, stratified by difficulty levels, targeting specific functions. An avatar guides real-time movements, offering visual references. Adjustable parameters include duration, repetitions, difficulty, speed, movement amplitude. Both technologies facilitate TR sessions via a dedicated platform, that can occur in real-time, involving interaction with patients, or independently with continuous monitoring by clinical staff.
Study: NCT05229120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking
Description: The adapted episodic future thinking (EFT) intervention will focus on generation of vivid, substance-free, rewarding events that could happen in the future with their children.
Study: NCT05864300

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurocheck frequency
Description: Randomized to hourly or every-other-hour examinations

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurocheck frequency
Description: Randomized to hourly or every-other-hour examinations
Study: NCT06245291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imdusiran
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imdusiran
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imdusiran
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: intravenous injection
Study: NCT06288412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Participants will receive insulin icodec subcutaneous (s.c.) once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Description: Participants will receive insulin degludec s.c. once daily.
Study: NCT05977452

Intervention type: DIAGNOSTIC_TEST
Intervention: Michigan Risk Score, Caprini Risk Assessment Model , Maneval scale
Description: Patients with PICC placement will be assessed by the Michigan Risk Score, Caprini Risk Assessment Model , Maneval scale（Chinese version） to predict the risk of PICC-related thrombosis. The time of evaluation are the day during PICC placement, 24-48h after PICC placement, and every time when patients receive PICC maintenance.
Study: NCT05197582

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tele-monitoring
Description: The symptoms of the patients were evaluated by calling the patients on the 1st, 5th, and 9th days of the quarantine by the researchers.
Study: NCT05968755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A chatbot designed to promote PrEP awareness and uptake for Black MSM
Description: Participants in the intervention group will have access to a theory-informed (Self-Determination Theory) chatbot and receive an automated personalized question message (root-node message) from the chatbot. The root-node messages are questions written into the chatbot algorithms to initiate interactive communication with participants. In each round of the interactive communication, the chatbot will provide automated personalized PrEP-related information, autonomous motivation, and psychological needs based on Self-Determination Theory constructs.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General educational messages
Description: Participants in the control group will received general education messages from a research assistant including healthy diet, exercise, and COVID-19 prevention. The frequency of contact will be pre-specified by participants in interviews prior to the RCT.
Study: NCT06200727

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF membrane tamponade surgery in macular hole
Description: A specially formulated PRF membrane, as described previously, was filled into the macular hole to promote fissure repair.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILM peeling in macular hole
Description: The treatment of the macular hole was ILM peeling.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF membrane grafting in pterygium
Description: Used of autologous PRF membrane to cover the exposed conjunctiva after pterygium excision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous conjunctival transplantation in pterygium
Description: Used of autologous conjunctiva to cover exposed sclera after pterygium excision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous PRF membrane grafting in trabeculectomy for glaucoma
Description: Used of autologous PRF membranes to cover the exposed sclera after trabeculectomy for glaucoma.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic membrane in trabeculectomy for glaucoma
Description: Used of amniotic to cover the exposed sclera after trabeculectomy for glaucoma.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF membrane grafting incorneal ulcer
Description: After surgical debridement of corneal ulcers, autologous PRF membrane was placed over the corneal wound to promote corneal healing
Study: NCT06228846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY001
Description: Oral
Study: NCT05559125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1002 Injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1002 Injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1002 Injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1002 Injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1005 Injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1005 Injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1005 Injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1005 Injection
Description: Intravenous injection
Study: NCT06480552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-56278
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-56278
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-56278
Description: Administered intravenously
Study: NCT06200727

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic membrane in corneal ulcer
Description: After surgical debridement of corneal ulcers, autologous amniotic membrane was placed over the corneal wound to promote corneal healing
Study: NCT06293885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 50
Description: a solution of 50% glucose (D50) will be injected into your pleural space

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care - No Dextrose 50
Description: Standard of Care
Study: NCT06521359

Intervention type: DEVICE
Intervention: flow cytometry
Description: Two ml of peripheral venous blood samples will be collected in heparinized tubes from patients and controls for assessment of levels of TFH and TFReg cells by flow cytometry.

Intervention type: DEVICE
Intervention: flow cytometry
Description: Two ml of peripheral venous blood samples will be collected in heparinized tubes from patients and controls for assessment of levels of TFH and TFReg cells by flow cytometry.
Study: NCT05045976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based interactive self-management support program
Description: The intervention group will receive a 60-90 minute introduction to the web-based interactive self-management support program. They will be instructed to do the weekly online self-assessment on symptoms, emotion, and health behaviors and how to use the web-based program to manage their health by applying self-manage skills and behavior change techniques. The contents of the interactive colorectal cancer self-management website include the following five main components: Health Support Station, Knowledge Supply Station, Sharing Stories, My Dear Friend, and Asking a Nurse.
Study: NCT05757661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focal Vibration
Description: A single 30-minute focal vibration procedure will be performed on both quadriceps with the V-Plus Wintecare® machine.~Three channels will be used on the muscle bellies of the rectus anterior, vastus internus and vastus externus. The positioning of the vibration heads will be done with straps designed by the manufacturer to keep the vibration focus stable on the muscle belly.~The configuration of the vibration program will be in an automatic mode of 10 seconds of vibration and 3 seconds of rest to avoid the coupling of the mechanoreceptors. The frequency used will be between 60 Hz to 150 Hz with a power of 80%.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Group
Description: The same procedure of the intervention group will be performed but without the focal vibration head contacting the skin (sham). A sufficient space will be left between the head and the headgear so that the vibration does not touch the skin.
Study: NCT05985850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aurora 1:1 Drops (Indica)
Description: Aurora 1:1 Drops (Indica) is created by extracting cannabinoids and terpenes and the concentrated extract is then diluted in medium-chain triglyceride (MCT) oil for optimal use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Medium-chain triglyceride (MCT) oil with the same appearance, color, and taste as the Aurora 1:1 Drops (Indica).
Study: NCT06480552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously
Study: NCT06067269

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiparametric Magnetic Resonance Imaging
Description: Undergo multiparametric MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PSMA-PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04735432

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC
Description: Subcutaneous injection with efgartigimod PH20 SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod IV
Description: Intravenous infusion of efgartigimod
Study: NCT06110091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Behavioral Therapy Program
Description: Integrated Behavioral Therapy is a behavioral program that includes education, lifestyle habits management, cognitive, relaxation, and behavioral conditioning for nocturia and insomnia
Study: NCT05545566

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic ultrasound versus chest X-ray
Description: Perform un ultrasound test, in addition to Chest X-Ray (usual practice), few hours after the surgery (D0), the next day (D1) and 4 to 6 hours after drain removal.~The data are collected in the standardized protocol for the two type of imaging.~The thoracic ultrasound and the Chest X-Ray are performed, blindly each other, in the same position for the patient and the same suction level of drain.
Study: NCT06530342

Intervention type: OTHER
Intervention: The same evaluation methods were used for both groups.
Description: No treatment applied to participants and same evaluation methods used in all athletes.
Study: NCT06110091

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education Program
Description: Health Education Program modules focus on brain health and includes topics such physical activity, social engagement, sleep topics (e.g., changes in sleep that occur with aging, effects of poor sleep on health), medications/medical conditions, vision and hearing impairment.
Study: NCT04819087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires and Rehabilitation Programs
Description: Questionnaires and Rehabilitation Programs
Study: NCT04959812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Subjects will receive Sufentanil while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive a placebo pill while the effects of this placebo on tolerance to a hemorrhagic insult will be assessed.
Study: NCT05302362

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation using YMS-201B(YBrain, Daejeon, Korea)
Study: NCT06406829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively and 0.05 μg/kg/h for 48 hours after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug/kg/h intraoperatively and 0.05 μg/kg/h for 48 hours after surgery.
Study: NCT05506839

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention (videoconferencing)
Description: 1 hour videoconferencing sessions over 8 weeks with an English language learner partner.
Study: NCT06406829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: In the placebo group, the 0.9% saline is administered with the same volume at the same speed as the dexmedetomidine group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: In the placebo group, the 0.9% saline is administered with the same volume at the same speed as the dexmedetomidine group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local analgesic techniques
Description: The 10ml 1% ropivacaine will be diluted into a 20ml syringe . As for scalp nerve block, each nerve will be blocked separately with 1-2 mL 0.5% ropivacaine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local analgesic techniques
Description: The 10ml 1% ropivacaine will be diluted into a 20ml syringe . As for scalp nerve block, each nerve will be blocked separately with 1-2 mL 0.5% ropivacaine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no Local analgesic techniques
Description: No Local analgesic techniques will be given.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no Local analgesic techniques
Description: No Local analgesic techniques will be given.
Study: NCT05577585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 50 MG/ML
Description: See also Arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: See also Arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine 50 MG/ML
Description: Open Label Follow Up (up to 8 Infusions)
Study: NCT05107583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Pre-Exercise Meal
Description: Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a low-carbohydrate lunch meal (\<10% carbohydrate; 35% estimated energy requirements) 2.5 hours prior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate Pre-Exercise Meal
Description: Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having consumed a high-carbohydrate lunch meal (\~2.2 g/kg carbohydrate; 35% estimated energy requirements) 2.5 hours prior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasted Exercise
Description: Sixty minutes of cycling at 60% VO2peak will take place on a stationary bicycle ergometer at 16:00, after having skipped lunch, and having consumed nothing other than plain water since breakfast (08:00; 25% estimated energy requirements). Exercise will therefore commence after an 8 hour period of fasting.
Study: NCT05901324

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiotherapy (IMRT)
Description: 1.8 Gy of 4-6 MV X-ray to a total dose of 23.4 Gy (13 fractions) will be delivered.